BCLI · Brainstorm Cell Therapeutics Inc.
$0.88
-0.02 (-2.22%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed May 15, 2026
Market Cap
$9.71M
Shares
11.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.88
Open$0.90
Day$0.88–0.94
52W$0.46–1.69
Avg vol 30d22K
Short int46K · 0.4% float · 1.0d
Short vol26%
Last earningsNov 14, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
−2%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
34%
mid-range
Momentum
relative strength
1-month return
−12%
trailing
6-month return
+54%
trailing
YTD return
+60%
this year
Relative strength
+48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-86% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.41% of float · ▼ -22.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 1-yr range
Squeeze score
20
low risk · 0–100
Fundamentals
EPS growth
+52%
Y/Y
Free cash flow
$-7.0M
Balance sheet
$29.0K
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
13.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
34%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-86% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.41% of float · ▼ -22.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $1 · 34%
52-wk high $2
vs 200-day avg +20%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCLI
this stock
Brainstorm Cell Therapeutics Inc.
|
$9.71M | +60.0% | — | — | 0.4% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
5
- % held
- 0.0%
- Net QoQ
- -390.5K sh
- Top holder
- OSAIC HOLDINGS, INC.
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCLI | -4.4% | -12.0% | +54.4% | -12.0% | +60.0% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -2.0% | -9.7% | +48.1% | -9.7% | +53.0% |